Evidence map›Paper›PMID 35969234›Full record

ArticleCancer immunology research2022

TCR-Independent Metabolic Reprogramming Precedes Lymphoma-Driven Changes in T-cell Fate.

Rebecca S Hesterberg, Min Liu, Aya G Elmarsafawi, John M Koomen, Eric A Welsh, Stephen G Hesterberg, Sujeewa Ranatunga, Chunying Yang, Weimin Li, Harshani R Lawrence and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Cancer immunology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Rebecca S HesterbergDepartment of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0003-0472-7517
Min LiuProteomics & Metabolomics Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0003-2138-8000
Aya G ElmarsafawiDepartment of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0003-0082-8900
John M KoomenProteomics & Metabolomics Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0002-3818-1762
Eric A WelshBiostatistics & Bioinformatics Shared Resource, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0002-9302-3855
Stephen G HesterbergDepartment of Integrative Biology, University of South Florida, Tampa, Florida.ORCID 0000-0002-3607-1789
Sujeewa RanatungaChemical Biology Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0002-8565-5705
Chunying YangDepartment of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0001-8188-0860
Weimin LiDepartment of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0001-7815-0859
Harshani R LawrenceChemical Biology Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0002-9263-7775
Paulo C RodriguezDepartment of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0001-7480-6566
Anders E BerglundDepartment of Biostatistics & Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0002-0393-3530
John L ClevelandDepartment of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0002-7561-9065
Moffitt Cancer Center · USUniversity of South Florida · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
New Therapeutic Vulnerabilities for Aggressive B-Cell LymphomaR01CA241713 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI CLEVELAND, JOHN L. · 2020 to 2024
$2.7M
Developing Chemical Probes for Oncogenic Signaling PathwaysR50CA211447 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI Harshani R Lawrence · 2017 to 2026
$2.2M
Plant-derived extracts regulate immunosuppressive myelopoiesis in Breast cancer patientsR01CA262121 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI RODRIGUEZ, PAULO CESAR · 2021 to 2025
$2.1M
Functional reprogramming of tumor-MDSC through antibody-based therapies targeting Notch ligandsR01CA233512 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI RODRIGUEZ, PAULO CESAR · 2019 to 2023
$2.0M
Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumorsR01CA273034 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI RODRIGUEZ, PAULO CESAR · 2022 to 2025
$1.9M
Integrated Program in Cancer and Data Science (ICADS)T32CA233399 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI William Douglas Cress, Elsa R Flores · 2019 to 2026
$1.7M
NCI NIH HHS P30 CA076292NCI NIH HHS R01 CA233512NCI NIH HHS R01 CA241713NCI NIH HHS R01 CA262121NCI NIH HHS R01 CA273034NCI NIH HHS R50 CA211447NCI NIH HHS T32 CA233399
6 · The paper itself

Abstract

Chronic T-cell receptor (TCR) signaling in the tumor microenvironment is known to promote T-cell dysfunction. However, we reasoned that poorly immunogenic tumors may also compromise T cells by impairing their metabolism. To address this, we assessed temporal changes in T-cell metabolism, fate, and function in models of B-cell lymphoma driven by Myc, a promoter of energetics and repressor of immunogenicity. Increases in lymphoma burden most significantly impaired CD4+ T-cell function and promoted regulatory T cell (Treg) and Th1-cell differentiation. Metabolomic analyses revealed early reprogramming of CD4+ T-cell metabolism, reduced glucose uptake, and impaired mitochondrial function, which preceded changes in T-cell fate. In contrast, B-cell lymphoma metabolism remained robust during tumor progression. Finally, mitochondrial functions were impaired in CD4+ and CD8+ T cells in lymphoma-transplanted OT-II and OT-I transgenic mice, respectively. These findings support a model, whereby early, TCR-independent, metabolic interactions with developing lymphomas limits T cell-mediated immune surveillance.

Indexed as

LymphomaLymphoma, B-CellAnimalsCD4-Positive T-LymphocytesCell DifferentiationGlucoseMiceMice, TransgenicReceptors, Antigen, T-CellTumor MicroenvironmentGlucoseReceptors, Antigen, T-Cell

Identifiers

PMID35969234
PMCPMC9662872
OpenAlexW4291582763

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.